Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) has earned an average recommendation of “Reduce” from the nine ratings firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $28.00.
FMS has been the topic of a number of analyst reports. Truist Financial set a $28.00 target price on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. Weiss Ratings lowered Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, March 13th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research report on Tuesday, February 24th. Finally, The Goldman Sachs Group lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th.
Get Our Latest Stock Analysis on FMS
Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA Trading Down 0.9%
Shares of FMS opened at $22.36 on Thursday. The company’s fifty day simple moving average is $23.08 and its 200-day simple moving average is $24.06. The company has a market cap of $12.49 billion, a P/E ratio of 11.71, a P/E/G ratio of 2.14 and a beta of 0.89. The company has a current ratio of 1.26, a quick ratio of 0.92 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.94 and a twelve month high of $30.46.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported $1.69 EPS for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. The company had revenue of $5.95 billion for the quarter. As a group, analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.
In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.
See Also
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
